JP2017214417A5 - - Google Patents

Download PDF

Info

Publication number
JP2017214417A5
JP2017214417A5 JP2017157336A JP2017157336A JP2017214417A5 JP 2017214417 A5 JP2017214417 A5 JP 2017214417A5 JP 2017157336 A JP2017157336 A JP 2017157336A JP 2017157336 A JP2017157336 A JP 2017157336A JP 2017214417 A5 JP2017214417 A5 JP 2017214417A5
Authority
JP
Japan
Prior art keywords
group
alkyl
aryl
divalent
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017157336A
Other languages
English (en)
Japanese (ja)
Other versions
JP6496787B2 (ja
JP2017214417A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017214417A publication Critical patent/JP2017214417A/ja
Publication of JP2017214417A5 publication Critical patent/JP2017214417A5/ja
Application granted granted Critical
Publication of JP6496787B2 publication Critical patent/JP6496787B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017157336A 2013-03-06 2017-08-17 皮膚疾患を治療するためのホルミルペプチド受容体2アゴニストの使用 Expired - Fee Related JP6496787B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361773778P 2013-03-06 2013-03-06
US61/773,778 2013-03-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015561540A Division JP6196328B2 (ja) 2013-03-06 2014-03-04 皮膚疾患を治療するためのホルミルペプチド受容体2アゴニストの使用

Publications (3)

Publication Number Publication Date
JP2017214417A JP2017214417A (ja) 2017-12-07
JP2017214417A5 true JP2017214417A5 (enExample) 2019-01-31
JP6496787B2 JP6496787B2 (ja) 2019-04-03

Family

ID=50389505

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015561540A Expired - Fee Related JP6196328B2 (ja) 2013-03-06 2014-03-04 皮膚疾患を治療するためのホルミルペプチド受容体2アゴニストの使用
JP2017157337A Expired - Fee Related JP6496788B2 (ja) 2013-03-06 2017-08-17 皮膚疾患を治療するためのホルミルペプチド受容体2アゴニストの使用
JP2017157336A Expired - Fee Related JP6496787B2 (ja) 2013-03-06 2017-08-17 皮膚疾患を治療するためのホルミルペプチド受容体2アゴニストの使用
JP2019043933A Expired - Fee Related JP6672499B2 (ja) 2013-03-06 2019-03-11 皮膚疾患を治療するためのホルミルペプチド受容体2アゴニストの使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015561540A Expired - Fee Related JP6196328B2 (ja) 2013-03-06 2014-03-04 皮膚疾患を治療するためのホルミルペプチド受容体2アゴニストの使用
JP2017157337A Expired - Fee Related JP6496788B2 (ja) 2013-03-06 2017-08-17 皮膚疾患を治療するためのホルミルペプチド受容体2アゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019043933A Expired - Fee Related JP6672499B2 (ja) 2013-03-06 2019-03-11 皮膚疾患を治療するためのホルミルペプチド受容体2アゴニストの使用

Country Status (13)

Country Link
US (5) US20140256685A1 (enExample)
EP (1) EP2964214A1 (enExample)
JP (4) JP6196328B2 (enExample)
KR (2) KR102223384B1 (enExample)
CN (2) CN107714683A (enExample)
AR (1) AR095035A1 (enExample)
AU (3) AU2014226001B2 (enExample)
BR (2) BR112015021392B1 (enExample)
CA (3) CA3114347A1 (enExample)
HK (2) HK1219661A1 (enExample)
RU (1) RU2696487C2 (enExample)
TW (1) TW201446241A (enExample)
WO (1) WO2014138046A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115043C2 (uk) * 2011-10-26 2017-09-11 Аллерган, Інк. Амідні похідні n-карбамідзаміщених амінокислот як модулятори формілпептидного рецептора 1 (fprl-1)
KR20140145203A (ko) * 2012-04-16 2014-12-22 알러간, 인코포레이티드 포르밀 펩타이드 수용체 2 조절물질로서 (2-우레이도아세트아미도)알킬 유도체
JP6101788B2 (ja) 2012-05-16 2017-03-22 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd ALX受容体アゴニストとしての1−(p−トリル)シクロプロピル置換架橋スピロ[2.4]ヘプタン誘導体
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
RU2696487C2 (ru) * 2013-03-06 2019-08-02 Аллерган, Инк. Применение агонистов формилпептидного рецептора 2 для лечения дерматологических заболеваний
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
CN105377814B (zh) * 2013-07-16 2018-04-03 阿勒根公司 作为甲酰基肽受体调节剂的n‑脲取代的氨基酸的衍生物
WO2015007830A1 (en) 2013-07-18 2015-01-22 Actelion Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
WO2015116566A1 (en) * 2014-01-29 2015-08-06 Allergan, Inc. 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
CA2948876A1 (en) 2014-05-21 2015-11-26 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
JP6811241B2 (ja) * 2015-12-10 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ピペリジノンホルミルペプチド受容体2およびホルミルペプチド受容体1アゴニスト
WO2017172761A1 (en) 2016-03-28 2017-10-05 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
AU2017249047B2 (en) * 2016-04-12 2021-08-05 Allergan, Inc. Phenyl urea derivatives as N-formyl peptide receptor modulators
MX2019003867A (es) * 2016-10-06 2019-08-05 Daiichi Sankyo Co Ltd Derivado de urea.
GB2561540A (en) * 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
ES2799098B2 (es) * 2019-06-10 2021-12-10 Univ Madrid Carlos Iii Aptameros agonistas del receptor fpr2 y usos de los mismos

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
JPS63232846A (ja) 1987-03-20 1988-09-28 Haruo Ogura 新規な固定相担体
AU6909300A (en) * 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
WO2004022529A2 (en) * 2002-09-05 2004-03-18 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
KR20090121832A (ko) * 2008-05-23 2009-11-26 인제대학교 산학협력단 2-(2-히드록시벤조일)히드라진카르복시아미드 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를유효 성분으로 함유하는 선택적 면역 억제용 약학적 조성물
PT2362866E (pt) * 2008-11-11 2015-10-26 Signum Biosciences Inc Compostos de isoprenila e métodos dos mesmos
WO2010104307A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2011073918A2 (en) * 2009-12-16 2011-06-23 Actelion Pharmaceuticals Ltd Peptides as modulators of fprl1 and/or fprl2
AU2011270872A1 (en) * 2010-06-24 2013-01-31 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
AU2011336973A1 (en) * 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
CA2827005A1 (en) 2011-02-11 2012-08-16 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
WO2012174243A1 (en) 2011-06-17 2012-12-20 Allergan, Inc. D -serine for the treatment of visual system disorders
EP2731931A1 (en) 2011-07-11 2014-05-21 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
UA115043C2 (uk) * 2011-10-26 2017-09-11 Аллерган, Інк. Амідні похідні n-карбамідзаміщених амінокислот як модулятори формілпептидного рецептора 1 (fprl-1)
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8729096B2 (en) 2012-02-16 2014-05-20 Allergan, Inc. Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators
KR20140145203A (ko) * 2012-04-16 2014-12-22 알러간, 인코포레이티드 포르밀 펩타이드 수용체 2 조절물질로서 (2-우레이도아세트아미도)알킬 유도체
CN105007909B (zh) * 2013-03-06 2019-06-28 阿勒根公司 用于治疗眼部炎性疾病的甲酰基肽受体2激动剂的用途
RU2696487C2 (ru) * 2013-03-06 2019-08-02 Аллерган, Инк. Применение агонистов формилпептидного рецептора 2 для лечения дерматологических заболеваний
CN105377814B (zh) * 2013-07-16 2018-04-03 阿勒根公司 作为甲酰基肽受体调节剂的n‑脲取代的氨基酸的衍生物
WO2015042071A1 (en) 2013-09-19 2015-03-26 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
AU2014352922B2 (en) 2013-11-21 2018-06-07 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
CA2948876A1 (en) * 2014-05-21 2015-11-26 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators

Similar Documents

Publication Publication Date Title
JP2017214417A5 (enExample)
JP2017214418A5 (enExample)
JP2017066164A5 (enExample)
JP2017214416A5 (enExample)
JP2018009012A5 (enExample)
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
BR112015005331B8 (pt) Eletrólito de polímero em gel e dispositivo eletroquímico incluindo o mesmo
EP2594555A4 (en) HETEROCYCLIC CONNECTION AND P27-KIP-1 DEVICE
MX385158B (es) Derivados indol para uso en medicina.
TW200800945A (en) Macrocylic inhibitors of hepatitis c virus
DOP2010000219A (es) Derivados de ftalazinona
CY1120477T1 (el) Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων
CO6180506A2 (es) Inhibidores de la proteasa ns3 del hcv
ES2570177T3 (es) Compuesto heterocíclico
AR091858A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
RU2011135977A (ru) Производное n-ацилантраниловой кислоты или его соль
BR112012033690A2 (pt) sais de cálcio de compostos como agentes anti-inflamatórios, imunomodulares e antitroliferativos
EA201170522A1 (ru) Новые гетероциклические азотсодержащие соединения, их получение и их применение в качестве антибактериальных лекарственных средств
AR091857A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
JP2016529235A5 (enExample)
BR112018076686A2 (pt) composição para a remoção de composto que contém enxofre
JP2019500319A5 (enExample)
MA39205A1 (fr) Polymères contenant des amines primaires utiles en tant qu'inhibiteurs de tartre
EP1911755A4 (en) BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE